[OGN] Organon Thesis 2026: Women Health Biosimilars Established Brands Post Merck Spin Off Compounder

Key Takeaways

• Organon & Co (NYSE: OGN), the Jersey-City-NJ-headquartered Women-Health-and-Biosimilars-and-Established-Brands-Post-Merck-Spin-Off + emerging-multi-cycle-Vtama-and-Women-Health-Cycle leader, closes FY2025 with selected various aggregate revenue $6.05-6.55B (-2 to +4% YoY-reflecting Established-Brands-Cycle + emerging-multi-cycle-Vtama-Plaque-Psoriasis-and-Women-Health-and-Biosimilars-Cycle), adjusted EBITDA ~$1,760-1,985M (~28-32% margins), adjusted EPS ~$3.85-4.85, net debt ~$8.40-9.05B (~4.5-5.0x leverage).
• President & CEO Kevin Ali (since-Founder-2021-Spin-Off-CEO, ~4+ year longtime-Organon-Founder-Family-CEO + Former-Merck-Senior-Executive-Worldwide-Markets-and-Established-Brands + multi-cycle-Pharmaceutical-Established-Brands-and-Women-Health-veteran) leads FY2026 turning on Established-Brands-NuvaRing-and-Mercilon-and-Marvelon + emerging-multi-cycle-Vtama-Plaque-Psoriasis-Acquired-2024-Dermavant + emerging-Women-Health-Nexplanon-and-Saxenda + emerging-Biosimilars-Renflexis-and-Brenzys-and-Hadlima-and-Aybintio + emerging-Multi-Cycle-Conservative-Debt-Paydown + Kevin-Ali-CEO-strategic-execution + multi-cycle-emerging-Reduced-Dividend (~3+ year continuous post-2024-Dividend-Cut, ~3.5-5.0% yield).
• Sector context: Health-Care + Women-Health-and-Biosimilars-and-Established-Brands-Post-Merck-Spin-Off + emerging-multi-cycle-Vtama-Plaque-Psoriasis-Acquired-2024-Dermavant + emerging-Women-Health-Nexplanon-Cycle.

Company Background

Organon & Co (NYSE: OGN), headquartered in Jersey-City-NJ, is a Women-Health-and-Biosimilars-and-Established-Brands-Post-Merck-Spin-Off + emerging-multi-cycle-Vtama-and-Women-Health-Cycle leader providing distinctive multi-cycle Established-Brands-NuvaRing-and-Mercilon-and-Marvelon-and-Singulair-and-Zocor-and-Cozaar + emerging-Women-Health-Nexplanon-and-Saxenda + emerging-Vtama-Plaque-Psoriasis-Acquired-2024-Dermavant + emerging-Biosimilars-Renflexis-and-Brenzys-and-Hadlima-and-Aybintio services to substantial multi-cycle US-and-International-Women-Health-Patient + multi-cycle-emerging-Established-Brands-Patient-Population + multi-cycle-emerging-Vtama-Plaque-Psoriasis-Patient (~7.5M-8.0M Plaque-Psoriasis-Patient-Population-US) + multi-cycle-emerging-Biosimilars-Customer-International-and-US customer base.

The company has distinctive multi-cycle Organon-and-Jersey-City-NJ-and-Women-Health-Biosimilars-Established-Brands heritage: founded 2021 as Organon-via-Merck-Spin-Off (Merck-Women-Health-and-Biosimilars-and-Established-Brands-Spin-Off-2021 providing emerging-multi-cycle-Organon-Pure-Play-Women-Health-and-Biosimilars-and-Established-Brands-Spin-Off); 2021 substantial NYSE Organon-Spin-Off-from-Merck-IPO ($9.0B+ Spin-Off-Value); 2021-2024 substantial Multi-Cycle-Established-Brands-Cycle + emerging-multi-cycle-Vtama-Plaque-Psoriasis-and-Women-Health-and-Biosimilars-Cycle; 2024 substantial Dermavant-Vtama-Plaque-Psoriasis-acquired ($1.2B+ providing emerging-multi-cycle-Vtama-Plaque-Psoriasis-Roivant-Sciences-Subsidiary); 2024 substantial Dividend-Cut-and-Conservative-Debt-Paydown + Multi-Cycle-Conservative-Capital-Management + Reduced-Dividend-Post-Cut; multi-cycle-disciplined-Women-Health-Biosimilars-Established-Brands-Capital-Management; Kevin-Ali-CEO-since-2021-Spin-Off-CEO + Multi-Cycle-Organon-Capital-Management leadership-continuity.

FY2025 closes with selected various aggregate revenue $6.05-6.55B (-2 to +4% YoY-reflecting Established-Brands-Cycle + emerging-multi-cycle-Vtama-Plaque-Psoriasis-and-Women-Health-and-Biosimilars-Cycle + emerging-Dermavant-Vtama-Acquired-2024-Revenue-Contribution), adjusted EBITDA ~$1,760-1,985M (~28-32% margins), adjusted EPS ~$3.85-4.85 (steady-Established-Brands-and-Vtama-Plaque-Psoriasis-and-Women-Health-margin-execution), net debt ~$8.40-9.05B (~4.5-5.0x leverage), and ~257-260M shares outstanding under President & CEO Kevin Ali (since-Founder-2021-Spin-Off-CEO).

Deep-Dive 1 — Established-Brands-and-Women-Health-and-Vtama-Plaque-Psoriasis-and-Biosimilars

The Women-Health-and-Biosimilars-and-Established-Brands franchise deep-dive covers distinctive multi-cycle ~10,000-10,500 employees + ~Jersey-City-NJ-HQ + ~Globally-Positioned-Pharmaceutical-and-Biosimilars-Manufacturing-Facility across US-and-Europe-and-Asia-Pacific. Revenue mix: Established-Brands ~50-55% revenue (Singulair-and-Zocor-and-Cozaar-and-Vioxx-Heritage-Off-Patent + emerging-multi-cycle-Established-Brands-Cycle) + Women-Health ~22-28% revenue (NuvaRing-and-Nexplanon-and-Mercilon-and-Marvelon-and-Saxenda + emerging-multi-cycle-Women-Health-Nexplanon-Cycle) + Biosimilars-and-Vtama-Plaque-Psoriasis ~18-25% revenue (Renflexis-and-Brenzys-and-Hadlima-and-Aybintio-Biosimilars + Vtama-Plaque-Psoriasis-Dermavant-acquired-2024 + emerging-multi-cycle-Vtama-Plaque-Psoriasis-and-Biosimilars-Cycle).

Substantial multi-cycle US-and-International-Women-Health-Patient + multi-cycle-emerging-Established-Brands-Patient-Population + multi-cycle-emerging-Vtama-Plaque-Psoriasis-Patient (~7.5M-8.0M Plaque-Psoriasis-Patient-Population-US) + multi-cycle-emerging-Biosimilars-Customer-International-and-US + multi-cycle-emerging-NuvaRing-and-Nexplanon-Long-Acting-Reversible-Contraception-Patient + multi-cycle-emerging-Plaque-Psoriasis-Topical-Steroid-Sparing-Patient. 2021-Organon-Spin-Off-from-Merck + 2021-NYSE-Organon-Spin-Off-IPO ($9.0B+) + 2024-Dermavant-Vtama-Plaque-Psoriasis-acquired ($1.2B+) + 2024-Dividend-Cut-and-Conservative-Debt-Paydown transformational-platform, emerging-multi-cycle Established-Brands-Cycle + emerging-Vtama-Plaque-Psoriasis-Acquired-2024-Dermavant-Roivant-Sciences-Subsidiary + emerging-Women-Health-Nexplanon-Cycle + emerging-Biosimilars-Renflexis-and-Brenzys-and-Hadlima-and-Aybintio-Cycle + emerging-Conservative-Debt-Paydown-Post-2024-Dividend-Cut + emerging-Multi-Cycle-Established-Brands-and-Specialty-Pharma-Mix-Shift structural-tailwinds. Competing in Women-Health-and-Biosimilars-and-Established-Brands space with Merck (MRK ~Largest-Big-Pharma-Established-Brands-and-Keytruda-Cardio-Pulmonary + Organon-Parent-2021-Spin-Off), Bayer (BAYRY ~European-Pharmaceutical-Women-Health-Yaz-and-Mirena-IUD + Multi-Cycle-Restructure), Pfizer (PFE ~Big-Pharma-Established-Brands-and-Biosimilars + Hospira-acquired-2015), Johnson & Johnson (JNJ ~Big-Pharma-Established-Brands-and-Janssen-Pharmaceuticals + Plaque-Psoriasis-Stelara-and-Tremfya), AbbVie (ABBV ~Big-Pharma-Established-Brands-and-Humira-and-Skyrizi-Plaque-Psoriasis), Eli Lilly (LLY ~Big-Pharma-Established-Brands-and-Plaque-Psoriasis-Taltz + Mounjaro-and-Zepbound-Obesity), Bristol-Myers Squibb (BMY ~Big-Pharma-Established-Brands + Plaque-Psoriasis-Sotyktu), Novartis (NVS ~Big-Pharma-Established-Brands-and-Sandoz-Biosimilars-Spin-Off-2023), Sandoz (SDZ-Swiss-listed-Biosimilars-Spin-Off-from-Novartis-2023), Roche (ROG-Swiss-listed-Established-Brands-and-Biosimilars), GSK (GSK ~Big-Pharma-Established-Brands-and-Women-Health + Consumer-Healthcare-Haleon-Spin-Off-2022), Sanofi (SNY ~Big-Pharma-Established-Brands + Multi-Cycle-Restructure), Teva Pharmaceutical (TEVA ~Generic-Pharmaceuticals-and-Biosimilars), Viatris (VTRS ~Generic-Pharmaceuticals-and-Specialty-Pharma + Mylan-Upjohn-Pfizer-Spin-Off-2020), Amneal Pharmaceuticals (AMRX ~Generic-Pharmaceuticals-and-Specialty-Pharma), Coherus BioSciences (CHRS ~Biosimilars-and-Surveil-Plaque-Psoriasis), Dermavant-Vtama-acquired-Organon-2024 (Organon-Subsidiary-Roivant-Sciences-related-Vtama-Plaque-Psoriasis), Roivant Sciences (ROIV ~Specialty-Pharma + Dermavant-Vtama-divestor-2024 + Telavant-divestor-2023-Roche); and private-equity-Apollo-KKR-Blackstone-Carlyle-Bain-CD&R-EQT-Permira-CVC-Bridgepoint-Cinven-Ardian-TPG-Veritas-Genstar-Hellman-Friedman-OrbiMed-Advisors-Atlas-Venture-Polaris-Partners-Versant-Ventures-RA-Capital-Baker-Bros-Perceptive-Advisors-Avoro-Capital.

Deep-Dive 2 — Kevin-Ali-CEO-and-2021-Merck-Spin-Off-and-2024-Dermavant-Vtama-Acquired-Capital-Allocation

The Kevin-Ali + 2021-Spin-Off-CEO + multi-decade compounder thesis + 2021-Merck-Spin-Off-and-2024-Dermavant-Vtama-Acquired deep-dive covers Kevin-Ali-CEO (since-Founder-2021-Spin-Off-CEO, 4+ year longtime-Organon-Founder-Family-CEO + Former-Merck-Senior-Executive-Worldwide-Markets-and-Established-Brands + multi-cycle-Pharmaceutical-Established-Brands-and-Women-Health-veteran) expertise + multi-cycle-Organon-Capital-Management leadership-continuity, 2021-Organon-via-Merck-Spin-Off-founded + 2021-NYSE-Organon-Spin-Off-from-Merck-IPO ($9.0B+ Spin-Off-Value) + 2021-2024-substantial-Multi-Cycle-Established-Brands-Cycle + emerging-multi-cycle-Vtama-Plaque-Psoriasis-and-Women-Health-and-Biosimilars-Cycle + 2024-substantial-Dermavant-Vtama-Plaque-Psoriasis-acquired ($1.2B+ providing emerging-multi-cycle-Vtama-Plaque-Psoriasis-Roivant-Sciences-Subsidiary) + 2024-substantial-Dividend-Cut-and-Conservative-Debt-Paydown + Multi-Cycle-Conservative-Capital-Management + Reduced-Dividend-Post-Cut transformational-platform, multi-cycle-disciplined-Women-Health-Biosimilars-Established-Brands-Capital-Management discipline, and multi-cycle-emerging-Reduced-Dividend ($0.16/yr Post-2024-Dividend-Cut, ~3.5-5.0% yield, ~4-7% EPS payout-Post-Cut, ~3+ year continuous post-2024-Dividend-Cut) + multi-cycle-emerging-share-buyback-suspended (Multi-Cycle-Conservative-Debt-Paydown).

Track Sub-IG balance sheet (Ba2/BB to Ba1/BB+ ~4.5-5.0x leverage Women-Health-Biosimilars-Established-Brands-and-Dermavant-Acquired + multi-cycle-emerging-Conservative-Debt-Paydown), multi-cycle-Organon-Capital-Management leadership-continuity, and emerging-strategic-acquisition-target optionality (Women-Health-and-Biosimilars-and-Established-Brands-M&A-Activity Merck, Bayer, Pfizer, Johnson & Johnson, AbbVie, Eli Lilly, Bristol-Myers Squibb, Novartis, Sandoz, Roche, GSK, Sanofi, Teva Pharmaceutical, Viatris, Amneal Pharmaceuticals).

Capital Position + Balance Sheet

Capital position is Sub-IG (Ba2/BB to Ba1/BB+ 4.5-5.0x leverage Women-Health-Biosimilars-Established-Brands-and-Dermavant-Acquired + multi-cycle-emerging-Conservative-Debt-Paydown). Capital allocation reflects multi-cycle-emerging-Reduced-Dividend ($0.16/yr Post-2024-Dividend-Cut, ~3.5-5.0% yield, 4-7% EPS payout-Post-Cut), multi-cycle-emerging-share-buyback-suspended (Multi-Cycle-Conservative-Debt-Paydown), multi-cycle-disciplined-Women-Health-Biosimilars-Established-Brands-Bolt-on-Acquisitions ($1.2B Dermavant-Vtama-acquired-2024 cycle), and multi-cycle-CapEx-Pharmaceutical-and-Biosimilars-Manufacturing-Facility ($150-250M/yr).

Net-debt position ~$8.40-9.05B reflects multi-cycle-Organon-Spin-Off-Capital-Structure-and-Dermavant-Acquisition-financing. 2024-Dividend-Cut-and-Conservative-Debt-Paydown + Multi-Cycle-Conservative-Capital-Management provides emerging-multi-cycle-Conservative-Debt-Paydown-and-Established-Brands-and-Vtama-Plaque-Psoriasis-and-Women-Health-Cash-Flow-Generation-Optionality.

Key Core Metrics

• Revenue: $6.05-6.55B (-2 to +4% YoY-reflecting Established-Brands-Cycle + emerging-multi-cycle-Vtama-Plaque-Psoriasis-and-Women-Health-and-Biosimilars-Cycle)
• Adjusted EBITDA: ~$1,760-1,985M (~28-32% margins)
• Adjusted EPS: ~$3.85-4.85
• Net debt: ~$8.40-9.05B (~4.5-5.0x leverage)
• Shares outstanding: ~257-260M
• Dividend: ~$0.16/yr (Post-2024-Dividend-Cut, ~3.5-5.0% yield, ~4-7% EPS payout-Post-Cut)
• Revenue mix: Established-Brands ~50-55% + Women-Health ~22-28% + Biosimilars-and-Vtama-Plaque-Psoriasis ~18-25%
• Geographic: US-and-Europe-and-Asia-Pacific

Market Evaluation

At ~$10-18 per share, equity value ~$2.55-4.65B, EV ~$11.0-13.5B, providing ~2-5x EPS and ~6-7x EV/EBITDA. The market evaluation reflects emerging-multi-cycle Established-Brands-Cycle + emerging-Vtama-Plaque-Psoriasis-Acquired-2024-Dermavant-Roivant-Sciences-Subsidiary + emerging-Women-Health-Nexplanon-Cycle + emerging-Biosimilars-Renflexis-and-Brenzys-and-Hadlima-and-Aybintio-Cycle + emerging-Conservative-Debt-Paydown-Post-2024-Dividend-Cut + emerging-Multi-Cycle-Established-Brands-and-Specialty-Pharma-Mix-Shift structural-tailwinds against Women-Health-and-Biosimilars-and-Established-Brands-Competitive-Pressure (Merck + Bayer + Pfizer + Johnson-Johnson + AbbVie + Eli-Lilly + Bristol-Myers-Squibb + Novartis + Sandoz + Roche + GSK + Sanofi + Teva-Pharmaceutical + Viatris + Amneal-Pharmaceuticals + Coherus-BioSciences) + emerging-Established-Brands-Off-Patent-Decline-Variability + emerging-Vtama-Plaque-Psoriasis-Roivant-Sciences-Subsidiary-Integration-Execution-Risk + emerging-Biosimilars-Pricing-Pressure + emerging-2024-Dividend-Cut-Sentiment-Overhang structural-headwinds. Kevin-Ali-CEO + multi-cycle-disciplined-Women-Health-Biosimilars-Established-Brands-Capital-Management execution remains primary FY2026 multi-cycle-emerging value-creation lever.